Company
Serapha Bio
Precision Editing. Transforming the Course of Disease.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
SERP-01 is a proprietary in vivo base editing program currently in a Phase 1/2 clinical trial for the treatment of AATD with the PiZZ genotype, the most severe genetic mutation responsible for >90% of AATD cases. SERP-01 is designed to restore production of functional M-AAT while reducing toxic Z-AAT, with the potential to address both the liver and lung manifestations of AATD with a single intravenous administration.
Products
- Other
- SERP-01
Loading relationship preview